Burns
Volume 31, Issue 7 , Pages 874-877 , November 2005

Comparison of silver-coated dressing (Acticoat™), chlorhexidine acetate 0.5% (Bactigrass®), and fusidic acid 2% (Fucidin®) for topical antibacterial effect in methicillin-resistant Staphylococci-contaminated, full-skin thickness rat burn wounds

  • Ersin Ülkür

      Affiliations

    • Gulhane Military Medical Academy and Medical Faculty of Haydarpasa Training Hospital, Department of Plastic and Reconstructive Surgery and Burn Unit, Istanbul, Turkey
    • Corresponding Author InformationCorresponding author at: GATA Haydarpasa Egitim Hastanesi Plastik ve Rekonstruktif Cerrahi Klinigi ve Yanık Unitesi, Üsküdar, Istanbul, Turkey. Tel.: +90 216 346 26 00x2656/532 470 76 59; fax: +90 216 348 78 80.
    • ,
  • Oral Oncul

      Affiliations

    • Gulhane Military Medical Academy and Medical Faculty of Haydarpasa Training Hospital, Department of Infectious diseases, Istanbul, Turkey
    • ,
  • Huseyin Karagoz

      Affiliations

    • Gulhane Military Medical Academy and Medical Faculty of Haydarpasa Training Hospital, Department of Plastic and Reconstructive Surgery and Burn Unit, Istanbul, Turkey
    • ,
  • Esma Yeniz

      Affiliations

    • Gulhane Military Medical Academy and Medical Faculty of Haydarpasa Training Hospital, Department of Infectious diseases, Istanbul, Turkey
    • ,
  • Bahattin Çeliköz

      Affiliations

    • Gulhane Military Medical Academy and Medical Faculty of Haydarpasa Training Hospital, Department of Plastic and Reconstructive Surgery and Burn Unit, Istanbul, Turkey

,Accepted 1 May 2005.

References 

  1. Greefield E, McManus AT. Infection complication: prevention and strategies for their control. Nurs Clin North Am. 1997;32:297–309
  2. Wiseman DM, Rovee DT, Alvarez OM. Wound dressings: design and use. In:  Cohen IK,  Diegelman RF,  Lindblad WJ editor. Wound healing: biochemical & clinical aspects. Philadelphia: WB Saunders; 1992;p. 562–600
  3. Gang RK, Sanyal SC, Bang RL, Mokaddas E, Lari AR. Staphylococcal septicemia in burns. Burns. 2000;2:359–366
  4. Acıkel C, Oncul O, Ulkur E, Bayram I, Celikoz B, Cavusoglu S. Comparison of silver sulfadiazine 1%, mupirocin 2%, and Fusidic acid 2% for topical antibacterial effect in methicillin-resistant staphylococci-infected, full-skin thickness rat burn wounds. J Burn Care Rehabil. 2003;24:37–41
  5. Fraser JF, Bodman J, Sturgess R, Faoagali J, Kimble RM. An in vitro study of the anti-bacterial efficacy of a 1% silver sulphadiazine and 0.2 chlorhexidine Digluconate cream, 1% silver sulphadiazine cream and a silver coated dressing. Burns. 2004;30:35–41
  6. Smoot EC, Kucan JO, Graham DR, Barenfanger JE. Susceptibility testing of topical antimicrobials against methicillin-resistant Staphylococcus aureus. J Burn Care Rehabil. 1992;13:198–202
  7. Walker HL, Mason AD. A standard animal burn. J Trauma. 1968;8:1049–1051
  8. Heggers JP, Hawkins H, Edgar P, Villarreal C, Herndon DN. Treatment of infection in burns. In: Herndon DN, editor. Total burn care. 2nd ed. London: WB Saunders Company Ltd; p. 120.
  9. Klasen HJ. Historical review of the use of silver in the treatment of burns. I. Early uses. Burns. 2000;26:117–130
  10. Dunn K, Edwards-Jones V. The role of Acticoat™ with nanocrystalline silver in the management of burns. Burns. 2004;30(Suppl. 1):S1–S9
  11. Bragg PD, Rainnie DJ. The effect of silver ions on the respiratory chain of E. coli. Can J Microbiol. 1974;20:883–889
  12. Modak SM, Fox CL. Binding of silver sulphadizine to the cellular components of Pseudomonas aeruginosa. Biochem Pharmacol. 1973;22:2391–2404
  13. Wright JB, Lam K, Hanson D, Burrel RE. Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control. 1999;27:344–350
  14. Fox C. Silver sulphadiazin: a new topical therapy for pseudomonas in burns. Arch Surg. 1968;96:184
  15. Winkelman W, Gratton D. Topical antibacterials. Clin Dermatol. 1989;7:156–162
  16. Shanson DC. Clinical relecance of resistance to Fusidic acid in Staphylococcus aureus. J Antimicrob Chemother. 1990;25:15–21
  17. Faber M, Rosdahl VT. Susceptibility to Fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption. J Antimicrob Chemother. 1990;25:7–14
  18. In:  Mandell GL,  Bennett JE,  Dolin R editor. Principles and practice of infectious diseases. New York: Churcill Livingstone; 1995;p. 428
  19. Gilbert M. Topical 2% versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol. 1989;20:1083–1087
  20. White DG, Collins PO, Rowsell RB. Topical antibiotics in the treatment of superficial skin infections in general practice-a comparison of mupirocin with sodium fusidate. J Infect. 1989;18:221–229
  21. Rosenberg A, Alatary SD, Peterson AF. Safety and efficacy of the antiseptic chlorhexidine gluconate. Surg Gynecol Obstet. 1976;143:789–792

PII: S0305-4179(05)00149-X

doi: 10.1016/j.burns.2005.05.002

Burns
Volume 31, Issue 7 , Pages 874-877 , November 2005

Article Tools

* Image Usage & Resolution